key: cord-0838448-3w1e5619
authors: Jardine, Jennifer; Morris, Edward
title: COVID-19 in Women’s Health: Epidemiology
date: 2021-03-31
journal: Best Pract Res Clin Obstet Gynaecol
DOI: 10.1016/j.bpobgyn.2021.03.010
sha: 3768216b0864ecc8c31e47a434c7d71909786d3f
doc_id: 838448
cord_uid: 3w1e5619

The disease COVID-19 emerged in late 2019 in Wuhan, China, and rapidly spread causing a pandemic which is ongoing and has resulted in more than two million deaths worldwide. COVID-19 is caused by the SARS-CoV-2 virus, which spreads effectively by direct contact with an infected person or contaminated surface, droplet or aerosol transmission. Vertical transmission, if it does occur, is rare. Among women of childbearing age, most will have mild or asymptomatic infection; severe illness is uncommon. Severe illness is more common in the later stages of pregnancy, when it is associated with complications including intensive care admission, maternal death and an increased risk of iatrogenic preterm birth. Women who are older, from minority ethnic groups, who are overweight or obese, who have comorbidities, or who live with socioeconomic deprivation are more likely to experience severe illness than women without these characteristics.

The COVID- 19 pandemic Background to the pandemic The 20 th and early 21 st century saw the emergence of a number of respiratory viruses which caused epidemics and pandemics, the most serious of which was the 'Spanish' influenza pandemic in 1918-20 which resulted in an estimated 50 million fatalities worldwide. [1] There was, prior to the emergence of SARS-CoV-2, broad expectation of a similar pandemic in the near future. [2, 3] Coronaviruses Coronaviruses are enveloped viruses with a single-strand RNA genome, which cause respiratory and intestinal infection in humans, other mammals and birds. When observed using an electron microscope, spike projections from the virus membrane appear like a crown, giving the name coronavirus from the Latin 'corona'. [4, 5] Seven coronaviruses are known to infect humans. Of these, four are responsible for the "common cold" upper respiratory tract illness, which is usually mild and self-limiting but can cause severe illness in the very young, the very old and the immunosuppressed; these were first described in the 1960s. In the first 19 years of the 21 st century, two further coronaviruses emerged in humans: Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) in 2002-3 in Guangdong province, China [6, 7] and Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in the Middle East in 2012. [8] These coronaviruses likely originated in bats and were transmitted to humans via civets in wet markets and dromedary camels respectively. [5] Both led to limited epidemics of severe illness with a high level of deaths: SARS-CoV to 26 countries, with more than 8,000 reported cases and 774 deaths, while MERS-CoV was mostly confined to the Middle East with 2,494 cases and 858 deaths. [9] Emergence and Spread of COVID-19

The initial outbreak of COVID-19 consisted of a cluster of patients with viral pneumonia in Wuhan, Hubei Province, China at the end of 2019. It is likely that the virus originated in bats. [10] It is unknown when SARS-CoV-2 first was transmitted to humans, and whether there was an intermediate vector.

The number of new infections generated per day by each infected person, in a population where everyone is vulnerable to be infected and controls on transmission are not in place J o u r n a l P r e -p r o o f Page 5 of 23 (Rt) has been estimated at between 2 and 4. [11] [12] [13] A symptomatic individual with mildmoderate disease is likely to be infectious for 24-48 hours prior to symptom onset. At 10 days following the onset of symptoms, 94% of individuals are no longer infectious. [14] The spread of COVID-19 has been tracked using genomic surveillance. [15, 16] When SARS-CoV-2 spreads from person to person, the virus accumulates small mutations, due to copying errors, merging of two different strains infecting the same host, or the host's immune response. [17] Together, these mutations create genomic 'fingerprints', which have been shared within the scientific community in an unprecedented manner. [18] This has allowed confident reporting of the origin of local and national outbreaks, and an understanding of international spread. [19, 20] Cases of COVID-19 have now been reported in every continent except Antarctica, with over 115 million cases and over 2.5 million deaths as of March 6, 2021.[21] Mutations and variants of SARS-CoV-2 SARS-CoV-2 is an RNA virus which is still in the process of adaptation to a human host; mutations affecting the transmission rate and clinical characteristics are expected. [17] While RNA viruses replicate more than DNA viruses, coronaviruses mutate less frequently than other RNA viruses as they encode a correcting enzyme, which modifies some of the errors which occur during viral replication. [22] At the time of writing, new variants of SARS-CoV-2 which are considered to be potentially more transmissible have emerged in the UK, South Africa and Brazil. These variants include a mutation to the receptor binding domain, which means they bind more easily to the J o u r n a l P r e -p r o o f Page 6 of 23 human receptor (ACE2) for SARS-CoV-2. This may make them more transmissible. The UK variant is estimated to be 56% more transmissible (95% CI: 50%-74%) than the previous dominant variants. [23] Transmission

Transmission of respiratory viruses occurs via three routes: (1) droplet transmission of respiratory secretions of an infected person, who is in close (considered by international authorities to be one or two metres) or direct contact, (2) direct contact with a contaminated surface; and (3) airborne transmission of smaller particles or droplets, suspended in air, which last longer and transmit further than droplets. [24] For SARS-CoV-2, there has been ongoing debate about the relative importance of these three routes of transmission. Droplet transmission, through close or direct contact with an infected person, is considered to be the primary route of transmission. [16, 24, 25] Early in the pandemic, spread from contaminated surfaces or objects (fomites) was considered potentially significant; recent evidence suggests that this contributes less to transmission than initially thought. [26] There is an accumulation of evidence that airborne transmission over longer distances, particularly in indoor spaces, is also important in the spread of SARS-COV-2. [27] [28] [29] J o u r n a l P r e -p r o o f

There is at present insufficient evidence to confirm that vertical (mother to child, either in utero or peripartum) transmission of SARS-CoV-2 occurs. [30] Shah et al. [31] proposed a set of criteria for determining whether an infection with SARS-CoV-2 could be considered congenital: appears not to be affected by mode of birth, method of feeding or whether the woman and baby are cared for together. [36] Methods to control transmission 

Within healthcare settings, implementation of many of the elements of transmission reduction is challenging if not impossible. Care of patients and others accessing care necessarily involves a high number of contacts between individuals, many of which cannot comply with social distancing guidelines. While the estimated secondary attack rate within healthcare settings is 0.7%-3.5% in systematic reviews, [42, 43] there is substantial heterogeneity between study estimates. The authors of one review noted that the studies available came from high and middle income countries, where PPE is likely to be readily available; in settings where this is not available, the transmission level is likely to be higher. Vaccines containing inactivated virus include the Chinese Sinopharm. [49] Although the vaccines licenced by EU and American bodies have passed assessments of reproductive toxicity using animal models, which look at both the fertility of the animals after exposure and teratogenicity during pregnancy, at the time of writing there exists no human trial data about the safety of using these vaccines in pregnancy. [50] 

The median incubation period of SARS-CoV-2 infection is estimated as 5.1 (95% CI 4.5 to 5.8) days, with the 95% upper percentile estimated as 11.7 (95% CI 9.7 to 14.2) days. [51, 52] A significant proportion of individuals infected with SARS-CoV-2 will have no symptoms. A systematic review estimated the proportion of infected individuals who remain asymptomatic throughout their infection to be 20% (95% CI: 17-25%).

The presentation of COVID-19 is heterogenous, with a broad range of symptoms.

Predominant symptoms are cough, sore throat, fever, myalgia or arthralgia, fatigue, headache and anosmia or ageusia (loss of senses of smell or taste, respectively). However, J o u r n a l P r e -p r o o f symptoms can also include nasal congestion, rash, and gastrointestinal effects such as anorexia, nausea and vomiting, and diarrhoea. [53] [54] [55] Effect on all women A large study in the UK population estimated that men were substantially more likely to die from COVID-19 than women (HR 1.59, 95% CI 1.53 to 1.65). [56] Severe symptoms, suggesting pneumonia and marked hypoxia, are more common in older people, the immunosuppressed and those with chronic conditions, such as diabetes, cancer or chronic lung disease. [56] Severe illness, such as that requiring intensive care unit (ICU) admission, is relatively uncommon in women of reproductive age. [57] While for many, the symptoms of COVID-19 improve quickly, it is evident that a substantial proportion of sufferers have prolonged symptoms ('long' or 'post acute' . [58, 59] In one survey, a quarter of those age 18-34 and nearly half of those age 50 or over were still experiencing symptoms two weeks following infection. [59] Effect on pregnant women Pregnant women do not appear more likely to contract the infection than the general population. Similar to the general population, most pregnant women who are infected with SARS-CoV-2 will remain asymptomatic or experience only mild or moderate cold/flulike symptoms. The PregCOV-19 Living Systematic Review is a programme to synthesise evidence on COVID-19 in pregnancy. [30] This review, which contained information on more than 11,000 women, found that the most common symptoms of COVID-19 in pregnant women were fever (40%) and cough (39%). Less frequent symptoms were dyspnoea, J o u r n a l P r e -p r o o f Page 12 of 23 myalgia, ageusia and diarrhoea, each present in more than 10% of women. In a small number of studies reporting universal screening, 74% (95% CI 51-93) of women were asymptomatic at the time of testing. [30] Pregnant women in the late stages of pregnancy appear to be more likely to experience severe morbidity. A UK registry study found that most women admitted to hospital with severe symptoms of COVID-19 in the first wave in the UK were in the late second or third trimester. [60] An analysis of women in French hospitals showed that those in the second half of pregnancy, from 20 weeks of gestation, were five times more likely to be admitted to ICU than those in the first half of pregnancy. [61] A large study from the USA, which included 406,446 women hospitalized for childbirth, of whom 6380 (1.6%) had COVID-19 (identified using hospital coding), found that women who gave birth with COVID-19 were at a substantially increased risk of ICU admission (3.3% of women), mechanical ventilation (1.3%) and death (0.1%) than those without COVID-19. [62] For women who are seriously unwell, there is a substantially increased risk of iatrogenic preterm birth: a large study which included global cohorts estimated a preterm birth rate among infected women of 16.2%. [63] The UK Obstetric Surveillance system found that women admitted to hospital with symptomatic SARS-CoV-2 infection were 11 times (aOR 11.43, 95% CI 5.07-25.75) more likely to have an iatrogenic preterm birth. [64] For pregnant women at earlier gestations, there is little conclusive evidence of increased risk. In some populations and studies, it has been concluded that all pregnant women are at increased risk; however, these studies do not stratify by gestation. 

The COVID-19 pandemic has further exposed marked inequalities in healthcare outcomes between individuals from less affluent socioeconomic groups and from non-white ethnic groups. Risk factors that appear to be associated with the likelihood of severe illness are:

• Being from a black, Asian and minority ethnic (BAME) background

• Being overweight (BMI 25-29 kg/m 2 ) or obese (BMI 30 kg/m 2 or more)

• Comorbidity, including pre-existing diabetes and chronic hypertension • Increased age, including for pregnant women aged 35 years or older • Living in areas or households of increased socioeconomic deprivation. [56, 60] In addition to these, the risk of becoming infected with COVID-19 is greater in individuals who are more exposed by working in healthcare or other public-facing occupations. [71] J o u r n a l P r e -p r o o f Page 14 of 23

The estimates of association with these risk factors are summarised in Table 1 , based on a large systematic review which did not estimate risks associated with ethnic group. [30] In the UK, a registry study found that compared to a historical cohort of women without SARS- there is no evidence that this also applies to women prior to 20 weeks' gestation. For babies in the neonatal period, the course of infection is mild. Women who are older, from minority ethnic groups, who are overweight or obese, who have comorbidities, or who live with socioeconomic deprivation are more likely to experience severe illness than women without these characteristics.

Acknowledgements: We acknowledge the support of the RCOG/RCM COVID-19 working group for their interpretation of evidence throughout the pandemic.

Conflicts of interest: EM is the President of the RCOG. JJ is employed by the RCOG.

Practice Points:

· Clinicians should be aware that pregnant women who are older, from minority ethnic groups, who are overweight or obese, who have comorbidities, or who live with socioeconomic deprivation are more likely to experience severe illness than women without these characteristics. · Pregnant women in the later stages of pregnancy seem to be at higher risk of experiencing severe disease than those at earlier gestations.

· Maternal infection with COVID-19 alone is not an indication for caesarean birth, formula feeding or separation of woman and baby, as the likelihood of transmission appears not to be affected by mode of birth, method of feeding or whether the woman and baby are cared for together.

Important areas for focus for future research include:

· The safety and efficacy of vaccination against COVID-19 in pregnant women · Persistence of symptoms in pregnant women · Care for pregnant women with long or sub-acute COVID-19

J o u r n a l P r e -p r o o f

The Spanish Influenza Pandemic: a lesson from history 100 years after 1918

Preparing intensive care for the next pandemic influenza

Trials at the ready: preparing for the next pandemic

Genetic Recombination, and Pathogenesis of Coronaviruses

Origin and evolution of pathogenic coronaviruses

Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China

Identification of a Novel Coronavirus in Patients with Severe Acute Respiratory Syndrome

Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia

Coronavirus covid-19 has killed more people than SARS and MERS combined, despite lower case fatality rate

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Early dynamics of transmission and control of COVID-19: a mathematical modelling study

Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2)

Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe

Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19

Transmission dynamics and evolutionary history of 2019-nCoV

Transmission dynamics of the COVID-19 outbreak and effectiveness of government interventions: A data-driven analysis

No evidence for increased transmissibility from recurrent mutations in SARS-CoV-2

disease and diplomacy: GISAID's innovative contribution to global health

Rapid implementation of SARS-CoV-2 sequencing to investigate cases of health-care associated COVID-19: a prospective genomic surveillance study

Tracking the COVID-19 pandemic in Australia using genomics

Genetic Variants of SARS-CoV-2-What Do They Mean?

Estimated transmissibility and severity of novel SARS-CoV-2 Variant of Concern

COVID-19 transmission-up in the air

Two metres or one: what is the evidence for physical distancing in covid-19?

Low risk of SARS-CoV-2 transmission by fomites in real-life conditions

Detection of air and surface contamination by SARS-CoV-2 in hospital rooms of infected patients

It is Time to Address Airborne Transmission of COVID-19

Scientific evidence supports aerosol transmission of SARS-COV-2

Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis

Classification system and case definition for SARS-CoV-2 infection in pregnant women, fetuses, and neonates

Characteristics and outcomes of neonatal SARS-CoV-2 infection in the UK: a prospective national cohort study using active surveillance

Transplacental transmission of SARS-CoV-2 infection

An Analysis of 38 Pregnant Women with COVID-19, Their Newborn Infants, and Maternal-Fetal Transmission of SARS-CoV-2: Maternal Coronavirus Infections and Pregnancy Outcomes

Analysis of SARS-CoV-2 vertical transmission during pregnancy

Maternal transmission of SARS-COV-2 to the neonate, and possible routes for such transmission: a systematic review and critical analysis

Closed environments facilitate secondary transmission of coronavirus disease 2019 (COVID-19) n.d

Reducing transmission of SARS-CoV-2

Quantifying the impact of physical distance measures on the transmission of COVID-19 in the UK

Strong Social Distancing Measures In The United States Reduced The COVID-19 Growth Rate

Household Transmission of SARS-CoV-2

What do we know about SARS-CoV-2 transmission? A systematic review and meta-analysis of the secondary attack rate and associated risk factors

SARS-CoV-2 setting-specific transmission rates: a systematic review and meta-analysis

SARS-CoV-2 (COVID-19) Superspreader Events

An mRNA Vaccine against SARS-CoV-2 -Preliminary Report

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Looking beyond COVID-19 vaccine phase 3 trials

Vaccinating the UK: how the covid vaccine was approved, and other questions answered

Incubation period of COVID-19: a rapid systematic review and meta-analysis of observational research

Epidemiology Based on Current Evidence

Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19 disease

Factors associated with COVID-19-related death using OpenSAFELY

ICNARC report on COVID-19 in critical care: England, Wales and Northern Ireland 8

Covid-19: What do we know about "long covid

Long-term Health Consequences of COVID-19

Characteristics and outcomes of pregnant women admitted to hospital with confirmed SARS-CoV-2 infection in UK: national population based cohort study

Are clinical outcomes worse for pregnant women ≥ 20 weeks' gestation infected with COVID-19? A multicenter case-control study with propensity score matching

Clinical Characteristics and Outcomes of Hospitalized Women Giving Birth With and Without COVID-19

Pregnancy and neonatal outcomes of COVID-19, co-reporting of common outcomes from the PAN-COVID and AAP SONPM registry

COVID-19 in pregnancy, et al. The incidence, characteristics and outcomes of pregnant women hospitalized with symptomatic and asymptomatic SARS-CoV-2 infection in the UK from

Update: Characteristics of Symptomatic Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status -United States

Pregnant women with severe or critical COVID-19 have increased composite morbidity compared to non-pregnant matched controls

Characteristics of Women of Reproductive Age with Laboratory-Confirmed SARS-CoV

Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records

Connecting the Dots on Vertical Transmission SARS-CoV-2 Using Protein-Protein Interaction Network Analysis -Potential roles of placental ACE2 and ENDOU

Vertical Transmission of COVID-19: A Systematic Review and Meta-analysis

Risk of hospital admission with coronavirus disease 2019 in healthcare workers and their households: nationwide linkage cohort study

Racial and Ethnic Disparities in COVID-19-Related Infections, Hospitalizations, and Deaths: A Systematic Review

J o u r n a l P r e -p r o o f Highlights:· COVID-19 is caused by the SARS-CoV-2 virus, which spreads by direct contact with an infected person or contaminated surface, droplet or aerosol transmission. · Pregnant women do not appear more likely to contract the infection than the general population.· The majority of pregnant women who contract the virus will have mild or moderate symptoms, but some will experience severe illness requiring hospitalization, intensive care admission, mechanical ventilation.